Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 7 (11), e48217

None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis


None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis

Wen-Juei Jeng et al. PLoS One.


Background & aims: A combination of pegylated interferon-alpha and ribavirin (PR) is the standard therapy for patients with chronic hepatitis C. The impact of polymorphism of interleukin-28B (IL28B) on sustained virological response (SVR) to PR has been well documented in patients with CHC genotype-1 (GT1), but it is controversial in genotype-2 (GT2) CHC patients. This study investigated the predictability of six single nucleotide polymorphisms (SNP) of IL28B on the treatment responses of PR in patients with CHC GT2.

Method: 197 CHC GT2 consecutive patients who received PR treatment in our prospective cohort were enrolled. Hepatitis C virus (HCV) genotyping, quantification of HCV-RNA and genotyping of the ten SNPs of IL28B were performed. Six SNPs of IL28B were chosen for analysis. The propensity score matching (PSM) analysis was applied using patients with CHC GT1 in another prospective cohort as a positive comparison to avoid covariate bias.

Results: The distribution of the six SNPs was similar in GT1 and GT2 patients. Five of these SNPs had strong association with treatment responses in GT1 but not in GT2 patients. After PSM analysis, these five SNPs still showed strong association with rapid virological response (RVR), cEVR and SVR in GT1 and had no influence in GT2 patients. Furthermore, rs12979860 and baseline viral load were the predictors for both RVR and SVR in GT1 patients. However, only baseline viral load could predict RVR and SVR in GT2 patients. In addition, in patients without RVR, rs12979860 was the only predictor for SVR in GT1 but no predictor for SVR was found in GT2.

Conclusions: The genetic polymorphisms of IL28B had no impact on treatment responses in GT2 patients.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.


Figure 1
Figure 1. The distribution of the ten SNPs of IL 28B between GT1 and GT2.
The genotypic distributions of the 10 SNPs of IL28B were similar in GT1 and GT2 patients (p>0.05).
Figure 2
Figure 2. The correlation of SNPs with SVR in GT1 and GT2 patients.
Six SNPs were chosen for analysis (rs12979860, rs8099917, rs12980275, rs8105790, rs7248668, 10853728). Five (rs12979860, rs8099917, rs12980275, rs8105790, and rs7248668) of these six SNPs revealed significant association with SVR in GT1 patients while none of them revealed any relationship between these SNPs and the SVR in GT2 patients.
Figure 3
Figure 3. The role of SNPs in RVR (3A), EVR (3B) and SVR (3C) between GT1 and GT2 after PSM analysis.
Five out of these SNPs (rs12979860, rs8099917, rs12980275, rs8105790, rs7248668) showed significant association with RVR, cEVR and SVR in GT1 patients but none of these SNPs had relationship with treatment responses in GT2 patients.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles


    1. Davis GL, Albright JE, Cook SF, Rosenberg DM (2003) Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9: 331–338. - PubMed
    1. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335–1374. - PubMed
    1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965. - PubMed
    1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982. - PubMed
    1. Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, et al. (2004) Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 41: 474–481. - PubMed

Publication types

MeSH terms

Grant support

This work was supported by NMRP: 98-3112-B-182A-003 and NMRP: 360021 from the National Science Council, Taiwan, and CMRPG 390682, 37542, 360463 from Chang Gung Memorial Hospital. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.